Quick Answer
RedHill Biopharma Ltd. reported R&D Expense of $1.59 million for fiscal year 2024.
RedHill Biopharma Ltd. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2024 | $1.59M | -55.0% |
| 2023 | $3.53M | -51.5% |
| 2022 | $7.28M | -75.3% |
| 2021 | $29.50M | +78.9% |
| 2020 | $16.49M | -5.3% |
| 2019 | $17.42M | -29.9% |
| 2018 | $24.86M | -24.6% |
| 2017 | $32.97M | +30.6% |
| 2016 | $25.24M | +42.0% |
| 2015 | $17.77M | — |
- RedHill Biopharma Ltd. showed a decrease of -55.0% in R&D Expense compared to the prior fiscal year.
- Over the 2015–2024 period, RedHill Biopharma Ltd.’s r&d expense has declined by 91.1% (from $17.77 million to $1.59 million).
- The most recent figure is from RedHill Biopharma Ltd.’s fiscal year 2024 report (Form 20-F), filed with the SEC on April 10, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: